Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retlirafusp Alfa vs Adebrelimab in Neoadjuvant Treatment of Locally Advanced ESCC
NCT07770672Phase 2Not yet recruiting
- Sponsor
- Lijie Biotech
- Start
- Aug 2026
- Primary completion
- Mar 2029
- Countries
- 1
01
Overview
A Phase 2 trial of retlirafusp alfa in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Lijie Biotech. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
retlirafusp alfa
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07770672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07770672.